Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30489364 | 0.95 | GABRR1 (0.39) | GABRR1SLC1A2SLC1A1F2RMEN1 | |
| SCHEMBL6057596 | 0.87 | GABRR1 (0.33) | GABRR1SLC1A2SLC1A1KDM4EPOLB | |
| SCHEMBL3389813 | 0.87 | GABRR1 (0.38) | GABRR1SLC1A2SLC1A1HSD11B1 | |
| SCHEMBL9019456 | 0.86 | SLC1A2 (0.39) | GABRR1SLC1A2SLC1A1KDM4EPOLB | |
| SCHEMBL12463875 | 0.86 | GABRR1 (0.41) | GABRR1SLC1A2SLC1A1 | |
| SCHEMBL19733794 | 0.84 | HSD11B1 (0.39) | GABRR1SLC1A2SLC1A1KDM4EPOLB | |
| SCHEMBL20979921 | 0.84 | HSD11B1 (0.39) | GABRR1SLC1A2SLC1A1KDM4EPOLB | |
| SCHEMBL20979912 | 0.84 | HSD11B1 (0.39) | GABRR1SLC1A2SLC1A1KDM4EPOLB | |
| SCHEMBL19733793 | 0.84 | HSD11B1 (0.39) | GABRR1SLC1A2SLC1A1KDM4EPOLB | |
| SCHEMBL20226843 | 0.84 | HSD11B1 (0.39) | GABRR1SLC1A2SLC1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797953-B1 | PROCESS FOR PRODUCING OXYGENIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20080064898-A1 | Method for Producing Oxygen-Containing Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1797953-A1 | PROCESS FOR PRODUCING OXYGENIC COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064898-A1 | Method for Producing Oxygen-Containing Compound | AOC2, AOX1, CAT | GABRR1 3962/4885SLC1A2 3536/4885SLC1A1 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.